Bortezomib in the Treatment of Acquired von Willebrand Disease Secondary to Monoclonal Gammopathy of Undetermined Significance

Authors

  • Kenneth Byrd University of Kansas School of Medicine - Wichita
  • Phu Truong

DOI:

https://doi.org/10.17161/kjm.v7i4.11507

Keywords:

von Willebrand diseases, bortezomib, monoclonal gammopathy of undetermined significance

Metrics

Metrics Loading ...

Downloads

Published

2014-11-06

Issue

Vol. 7 No. 4 (2014)

Section

Case Reports

License

All articles in the Kansas Journal of Medicine are licensed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND 4.0). 

 

How to Cite

Byrd, K., & Truong, P. (2014). Bortezomib in the Treatment of Acquired von Willebrand Disease Secondary to Monoclonal Gammopathy of Undetermined Significance. Kansas Journal of Medicine, 7(4), 167-170. https://doi.org/10.17161/kjm.v7i4.11507